

**Amendments to the Claims**

Please cancel Claims 1, 2, 4-15, 18, 19, and 21-32. The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

Claims 1-15 (Canceled)

16. (Withdrawn) An immunoassay method for detecting human TNF in a sample, comprising:
  - (a) contacting said sample with an antibody according to claim 36, or a TNF binding fragment thereof, in detectably labeled form; and
  - (b) detecting the binding of the antibody to said TNF.
17. (Original) The chimeric antibody cA2.

Claims 18-32 (Canceled)

33. (Withdrawn) An immunoassay method for detecting human TNF in a sample, comprising:
  - (a) contacting said sample with an antibody according to claim 38, or a TNF binding fragment thereof, in detectably labeled form; and
  - (b) detecting the binding of the antibody to said TNF.
34. (Canceled)
35. (Canceled)
36. (Canceled)
37. (Original) A chimeric antibody comprising at least part of a human IgG1 constant region and at least part of a non-human immunoglobulin variable region, said antibody capable

of binding an epitope specific for human TNF $\alpha$ , wherein the non-human immunoglobulin variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 5.

38. (Canceled)
39. (Canceled)
40. (Original) A polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 5 or at least one binding fragment thereof, wherein said polypeptide binds to hTNF $\alpha$ .
41. (Original) A polypeptide of Claim 40, wherein said polypeptide neutralizes hTNF $\alpha$ .
42. (Original) A polypeptide of Claim 40, wherein said polypeptide inhibits hTNF $\alpha$ .
43. (Canceled)
44. (Canceled)
45. (Original) A polypeptide of Claim 40 which competitively inhibits the binding of monoclonal antibody cA2 to hTNF $\alpha$ .
46. (Canceled)
47. (Canceled)
48. (Original) A polypeptide comprising at least one binding fragment of SEQ ID NO: 3, wherein said polypeptide binds to hTNF $\alpha$  and competitively inhibits the binding of monoclonal antibody cA2 to hTNF $\alpha$ .

49. (Original) A polypeptide comprising at least one binding fragment of SEQ ID NO: 5, wherein said polypeptide binds to hTNF $\alpha$  and competitively inhibits the binding of monoclonal antibody cA2 to hTNF $\alpha$ .
50. (Original) A polypeptide of Claim 45 having a hTNF $\alpha$  binding affinity, measured as an affinity constant (K<sub>a</sub>), of at least  $1 \times 10^8$  liters/mole.
51. (Original) A polypeptide of Claim 45 having a hTNF $\alpha$  binding affinity, measured as an affinity constant (K<sub>a</sub>), of at least  $1 \times 10^9$  liters/mole.
52. (Original) A polypeptide of Claim 45 which neutralizes hTNF $\alpha$  with an ID<sub>50</sub> of at least about 1  $\mu$ g/ml.
53. (Original) A polypeptide of Claim 45 which neutralizes hTNF $\alpha$  with an ID<sub>50</sub> of at least about 100 ng/ml.
54. (Original) A polypeptide of Claim 45 which neutralizes hTNF $\alpha$  with an ID<sub>50</sub> of at least about 15 ng/ml.
55. (Original) A fusion protein comprising SEQ ID NO: 3 or SEQ ID NO: 5 or a binding fragment thereof, wherein said fusion protein binds to hTNF $\alpha$ .